Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934</div>

| Filed by         
 the Registrant ¨ |     | Filed by a party other than the Registrant þ |

Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| þ | Soliciting Material Pursuant to §240.14a-12 |

<div align='center'>Staar Surgical Company

(Name of Registrant as Specified In Its Charter)

Alcon Inc.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| þ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

| www.alcon.com |

Alcon released the following press release and investor discussion materials on November 4, 2025 related to the proposed acquisition of STAAR Surgical Company.

<div align='center'>MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG</div>

Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders

GENEVA, November 4, 2025 –Alcon (SIX/NYSE: ALC), the
global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR
Surgical Company (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (SEC). Alcon plans to initiate outreach to STAAR stockholders
and the presentation highlights key considerations for these discussions, including:

| · | The                                                                                              
 proposed merger represents a premium that significantly exceeds the median premium of comparable 
 MedTech transactions and offers certain value to STAAR stockholders.1                            |

| · | The                                                                                                  
 Broadwood Partners-led opposition campaign is an attempt at a “silent takeover”                      
 of STAAR Surgical. Broad